Patrick J. Mcenany - 19 Nov 2024 Form 4 Insider Report for CATALYST PHARMACEUTICALS, INC. (CPRX)

Role
Director, Chairman of Board of Directors
Signature
/s/ Patrick J. McEnany
Issuer symbol
CPRX
Transactions as of
19 Nov 2024
Net transactions value
-$3,022,468
Form type
4
Filing time
21 Nov 2024, 17:11:39 UTC
Previous filing
15 Nov 2024
Next filing
25 Nov 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CPRX Common stock, par value $0.001 per share Options Exercise $348,141 +98,345 +2.2% $3.54 4,576,514 19 Nov 2024 Direct
transaction CPRX Common stock, par value $0.001 per share Sale $2,083,734 -98,345 -2.1% $21.19 4,478,169 19 Nov 2024 Direct F1, F2
transaction CPRX Common stock, par value $0.001 per share Options Exercise $256,650 +72,500 +1.6% $3.54 4,550,669 20 Nov 2024 Direct
transaction CPRX Common stock, par value $0.001 per share Sale $1,543,525 -72,500 -1.6% $21.29 4,478,169 20 Nov 2024 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CPRX Options to purchase common stock Options Exercise $0 -98,345 -5% $0.000000 1,865,245 19 Nov 2024 Common Stock 98,345 $3.54 Direct F4
transaction CPRX Options to purchase common stock Options Exercise $0 -72,500 -3.9% $0.000000 1,792,745 20 Nov 2024 Common Stock 72,500 $3.54 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares were sold for personal reasons, including paying federal income taxes and diversifying the Reporting Person's portfolio. Shares were not sold as a result of any disagreement with the Company. Mr. McEnany remains the non-executive chairman of the Company's Board of Directors and the Company's largest individual, non-institutional shareholder.
F2 Represents a weighted average price for the shares sold. Shares were sold in various lots ranging from $21.11 to $21.31 per share.
F3 Represents a weighted average price for the shares sold. Shares were sold in various lots ranging from $21.05 to $21.455 per share.
F4 Options vested in three equal tranches on May 29, 2019, 2020 and 2021.